Sign In
Buy CTMX
$3.16
-0.290 (-8.41%)
At Close: Jun 02, 2026
CytomX Therapeutics to Report First Quarter 2023 Financial Results on May 9, 2023
04:01pm, Monday, 01'st May 2023
SOUTH SAN FRANCISCO, Calif., May 01, 2023 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated, localized biologics, today announced that it w
CytomX Therapeutics to Present at the H.C. Wainwright BioConnect Investor Conference at NASDAQ
04:05pm, Tuesday, 25'th Apr 2023
SOUTH SAN FRANCISCO, Calif., April 25, 2023 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated, localized biologics, today announced that Se
CytomX Therapeutics, Inc. (CTMX) Q4 2022 Earnings Call Transcript
07:51pm, Monday, 27'th Mar 2023
CytomX Therapeutics, Inc. (NASDAQ:CTMX ) Q4 2022 Earnings Conference Call March 27, 2023 5:00 PM ET Company Participants Chris Ogden - SVP of Finance and Accounting Sean McCarthy - CEO and Chairman Co
CytomX Therapeutics (CTMX) Reports Q4 Loss, Lags Revenue Estimates
07:02pm, Monday, 27'th Mar 2023
CytomX Therapeutics (CTMX) delivered earnings and revenue surprises of -100% and 94.66%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
CytomX Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results on March 27, 2023
07:23pm, Wednesday, 22'nd Mar 2023
SOUTH SAN FRANCISCO, Calif., March 22, 2023 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated, localized biologics, today announced that it
CytomX Therapeutics to Present at Upcoming March Investor Conferences
04:05pm, Tuesday, 28'th Feb 2023
SOUTH SAN FRANCISCO, Calif., Feb. 28, 2023 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated, localized biologics, today announced that Sea
CytomX Therapeutics to Present at the B. Riley Securities Virtual Annual Oncology Investor Conference
04:05pm, Tuesday, 17'th Jan 2023
SOUTH SAN FRANCISCO, Calif., Jan. 17, 2023 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated, localized biologics, today announced that Sea
How to Start Investing in Penny Stocks in 2023
11:00am, Sunday, 08'th Jan 2023
Are you using these tips for investing in penny stocks? The post How to Start Investing in Penny Stocks in 2023 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
CytomX (CTMX) Up 55% on Strategic Partnership With Moderna
03:03pm, Friday, 06'th Jan 2023
CytomX (CTMX) inks an agreement with Moderna to develop therapeutics for oncology and non-oncology conditions. The company also provides its business outlook for 2023.
CytomX Therapeutics (CTMX) Stock Jumps 50% on Moderna Deal
02:45pm, Friday, 06'th Jan 2023
On a resoundingly positive Friday for the market, CytomX Therapeutics (NASDAQ: CTMX ) is providing a large portion of the fireworks. Specifically, CTMX stock skyrocketed more than 50% before settling
CytomX shares surge more than 50% on Moderna partnership
05:11pm, Thursday, 05'th Jan 2023
CytomX Therapeutics Inc. CTMX, +7.19% shares soared more than 50% in the extended session Thursday after the small biotech company announced a partnership with Moderna Inc. MRNA, -2.17% CytomX shares
CytomX Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
05:00pm, Tuesday, 20'th Dec 2022
SOUTH SAN FRANCISCO, Calif., Dec. 20, 2022 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated oncology therapeutics, today announced that Se
SOUTH SAN FRANCISCO, Calif., Dec. 07, 2022 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated oncology therapeutics, today announced that
Best Penny Stocks To Buy Now? 5 Biotech Stocks To Watch This Week
12:59pm, Monday, 21'st Nov 2022
Biotech penny stocks to watch this week. Are they a buy now?
CytomX (CTMX) Stock Surges on Oncology Deal With Regeneron
03:11pm, Friday, 18'th Nov 2022
CytomX (CTMX) gets a boost after its deal with Regeneron for the development of investigational next-generation bispecific immunotherapies.
